jRCT2041210004.

Study name	A clinical phase III study of favipiravir in patients with early onset COVID‐19 with risk factors for severe illness ‐ a placebo‐controlled, stratified randomised, multicenter, double‐blind study
Methods	Multicentre, randomized controlled study
Participants	COVID‐19 patients with risk factors for progression to severe disease onset within 72 hours prior to the start of study drug administration
Interventions	T‐705a tablets 200 mg administrated orally, 9 tablets twice daily for Day 1, and 4 tablets twice daily for Days 2 to 10.
Outcomes	Percentage of participants with severe disease from randomization to Day 28
Starting date	20 April 2021
Contact information	Name: Clinical Trial Information Officer Address: 2‐14‐1,Kyoubashi,Chuo‐ku,Tokyo, Japan Tokyo Japan 104‐0031 Telephone: +81‐3‐6228‐3129 E‐mail: fftc‐clinicaltrial‐info1@fujifilm.com
Notes